Log in

NASDAQ:MREOMereo BioPharma Group Stock Price, Forecast & News

-0.16 (-5.52 %)
(As of 08/6/2020 04:00 PM ET)
Today's Range
Now: $2.74
50-Day Range
MA: $3.02
52-Week Range
Now: $2.74
Volume313,637 shs
Average Volume214,288 shs
Market Capitalization$68.23 million
P/E RatioN/A
Dividend YieldN/A
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; MPH-966, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. The company also develops OMP-305B83 and OMP-313M32, which are anti-cancer therapeutic candidates in clinical development stage. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MREO



Sales & Book Value

Annual SalesN/A
Book Value$2.06 per share



Market Cap$68.23 million
Next Earnings Date9/15/2020 (Estimated)
OptionableNot Optionable
-0.16 (-5.52 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MREO News and Ratings via Email

Sign-up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Mereo BioPharma Group (NASDAQ:MREO) Frequently Asked Questions

How has Mereo BioPharma Group's stock been impacted by COVID-19 (Coronavirus)?

Mereo BioPharma Group's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MREO stock has increased by 76.8% and is now trading at $2.74.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Mereo BioPharma Group?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mereo BioPharma Group

When is Mereo BioPharma Group's next earnings date?

Mereo BioPharma Group is scheduled to release its next quarterly earnings announcement on Tuesday, September 15th 2020.
View our earnings forecast for Mereo BioPharma Group

Has Mereo BioPharma Group been receiving favorable news coverage?

Press coverage about MREO stock has been trending positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Mereo BioPharma Group earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Mereo BioPharma Group

Who are some of Mereo BioPharma Group's key competitors?

What other stocks do shareholders of Mereo BioPharma Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Nabriva Therapeutics (NBRV), OpGen (OPGN), Provention Bio (PRVB), VBI Vaccines (VBIV), Vaxart (VXRT), Aduro BioTech (ADRO), ImmunoGen (IMGN) and Arcus Biosciences (RCUS).

Who are Mereo BioPharma Group's key executives?

Mereo BioPharma Group's management team includes the following people:
  • Dr. Denise Scots-Knight, Co-Founder, CEO & Exec. Director (Age 60)
  • Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 50)
  • Dr. Alastair MacKinnon, Co-Founder & Chief Medical Officer (Age 49)
  • Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 62)
  • Mr. Richard Crispin Morgan Jones, CFO & Exec. Director (Age 53)

When did Mereo BioPharma Group IPO?

(MREO) raised $49 million in an initial public offering on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

What is Mereo BioPharma Group's stock symbol?

Mereo BioPharma Group trades on the NASDAQ under the ticker symbol "MREO."

How do I buy shares of Mereo BioPharma Group?

Shares of MREO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mereo BioPharma Group's stock price today?

One share of MREO stock can currently be purchased for approximately $2.74.

How big of a company is Mereo BioPharma Group?

Mereo BioPharma Group has a market capitalization of $68.23 million. The company earns $-44,490,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Mereo BioPharma Group employs 37 workers across the globe.

What is Mereo BioPharma Group's official website?

The official website for Mereo BioPharma Group is www.mereobiopharma.com.

How can I contact Mereo BioPharma Group?

Mereo BioPharma Group's mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The company can be reached via phone at 44-33-3023-7300.

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.